Cellectis SA (NASDAQ:CLLS) Receives Consensus Recommendation of “Buy” from Brokerages

Cellectis SA (NASDAQ:CLLS) has been given an average recommendation of “Buy” by the eight research firms that are covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $31.80.

Several brokerages recently weighed in on CLLS. Citigroup decreased their price objective on Cellectis from $37.00 to $22.00 and set a “neutral” rating for the company in a report on Monday, March 11th. BidaskClub lowered Cellectis from a “hold” rating to a “sell” rating in a report on Friday, May 24th. Zacks Investment Research raised Cellectis from a “hold” rating to a “buy” rating and set a $18.00 price objective for the company in a report on Tuesday, June 4th. Barclays reissued a “buy” rating and issued a $50.00 price objective on shares of Cellectis in a report on Wednesday, March 13th. Finally, ValuEngine raised Cellectis from a “sell” rating to a “hold” rating in a report on Monday, April 1st.

Shares of CLLS opened at $15.70 on Friday. Cellectis has a fifty-two week low of $14.85 and a fifty-two week high of $31.30. The stock has a market capitalization of $635.65 million, a P/E ratio of -8.13 and a beta of 1.85. The company has a quick ratio of 9.74, a current ratio of 9.77 and a debt-to-equity ratio of 0.07.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings data on Monday, March 11th. The biotechnology company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.14. Cellectis had a negative return on equity of 14.85% and a negative net margin of 401.24%. The company had revenue of $3.08 million during the quarter, compared to analyst estimates of $7.46 million. Sell-side analysts expect that Cellectis will post -2.32 earnings per share for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Nikko Asset Management Americas Inc. purchased a new position in Cellectis during the 1st quarter valued at about $15,084,000. Sumitomo Mitsui Trust Holdings Inc. purchased a new position in Cellectis during the 1st quarter valued at about $14,987,000. ARK Investment Management LLC grew its holdings in Cellectis by 30.8% during the 1st quarter. ARK Investment Management LLC now owns 934,076 shares of the biotechnology company’s stock valued at $17,131,000 after buying an additional 219,740 shares in the last quarter. New York State Common Retirement Fund purchased a new position in Cellectis during the 4th quarter valued at about $1,658,000. Finally, Hudson Bay Capital Management LP grew its holdings in Cellectis by 140.0% during the 4th quarter. Hudson Bay Capital Management LP now owns 90,000 shares of the biotechnology company’s stock valued at $1,499,000 after buying an additional 52,500 shares in the last quarter. 30.63% of the stock is owned by institutional investors.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.

Recommended Story: Limitations of the P/E Growth ratio

Analyst Recommendations for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.